DR. MARIANNE M. DO, O.D.
Optometry at Euclid St, Santa Ana, CA

License number
California 12982T
Category
Optometry
Type
Optometrist
Address
Address 2
15972 Euclid St #G, Santa Ana, CA 92708
548 S. CINNAMON WAY, Orange, CA 92866
Phone
(714) 531-7626

Personal information

See more information about MARIANNE M. DO at radaris.com
Name
Address
Phone
Marianne Do
548 Cinnamon Way, Orange, CA 92866

Professional information

Marianne Do Photo 1

Stabilization Of Mitochondrial Membranes In Ocular Diseases And Conditions

US Patent:
2009019, Aug 6, 2009
Filed:
Feb 6, 2008
Appl. No.:
12/026736
Inventors:
Lon T. Spada - Walnut CA, US
Wendy M. Blanda - Tustin CA, US
Marianne M. Do - Orange CA, US
Scott M. Whitcup - Laguna Hills CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Michael R. Robinson - Irvine CA, US
International Classification:
A61F 2/00, A61K 38/08
US Classification:
424427, 514 15
Abstract:
Methods of treating ocular diseases and conditions using biodegradable ocular implants containing cyclosporine to inhibit mitochondrial permeability transition pore formation are disclosed.


Marianne Do Photo 2

Intraocular Sustained Release Drug Delivery Systems And Methods For Treating Ocular Conditions

US Patent:
2010024, Sep 30, 2010
Filed:
Mar 25, 2009
Appl. No.:
12/411250
Inventors:
Michael R. ROBINSON - Irvine CA, US
James A. Burke - Santa Ana CA, US
Hui Liu - Irvine CA, US
Werhner C. Orilla - Anaheim CA, US
Lon T. Spada - Walnut CA, US
Scott Whitcup - Laguna Hills CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Kun Xu - Laguna Niguel CA, US
Marianne M. Do - Orange CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61F 2/00, A61K 31/215, A61K 31/165, A61K 9/14, A61K 31/4025, A61K 31/426, A61K 31/415, A61K 31/42
US Classification:
424426, 514530, 514622, 424501, 514422, 514369, 514385, 514376
Abstract:
Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between days and year.